ci 934 has been researched along with difloxacin in 3 studies
| Studies (ci 934) | Trials (ci 934) | Recent Studies (post-2010) (ci 934) | Studies (difloxacin) | Trials (difloxacin) | Recent Studies (post-2010) (difloxacin) |
|---|---|---|---|---|---|
| 33 | 0 | 2 | 127 | 7 | 18 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domagala, JM; Heifetz, CL; Hutt, MP; Mich, TF; Nichols, JB; Solomon, M; Worth, DF | 1 |
| Habiyaremye, I; Vandepitte, J; Verbist, L | 1 |
| King, A; Phillips, I | 1 |
3 other study(ies) available for ci 934 and difloxacin
| Article | Year |
|---|---|
1-Substituted 7-[3-[(ethylamino)methyl]-1-pyrrolidinyl]-6,8- difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids. New quantitative structure-activity relationships at N1 for the quinolone antibacterials.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Carboxylic Acids; Chemical Phenomena; Chemistry; Mice; Microbial Sensitivity Tests; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1988 |
[Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
Topics: Anti-Bacterial Agents; Campylobacter fetus; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fleroxacin; Fluoroquinolones; Naphthyridines; Norfloxacin; Ofloxacin; Oxazines; Pefloxacin; Quinolines; Salmonella; Shigella; Vibrio cholerae; Yersinia enterocolitica | 1987 |
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
Topics: Acinetobacter; Aeromonas; Anti-Bacterial Agents; Bacteria; Bacteria, Anaerobic; Ciprofloxacin; Enoxacin; Enterobacteriaceae; Fluoroquinolones; Gram-Positive Bacteria; Microbial Sensitivity Tests; Nalidixic Acid; Naphthyridines; Norfloxacin; Pefloxacin; Quinolines | 1986 |